• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胚系倾向性变异在各年龄段骨髓增生异常综合征患者中均有发生。

Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.

机构信息

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.

Section of Hematology, Oncology and Rheumatology, Department of Internal Medicine, Department of Medicine, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Blood. 2022 Dec 15;140(24):2533-2548. doi: 10.1182/blood.2022015790.

DOI:10.1182/blood.2022015790
PMID:35969835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9918848/
Abstract

The frequency of pathogenic/likely pathogenic (P/LP) germ line variants in patients with myelodysplastic syndrome (MDS) diagnosed at age 40 years or less is 15% to 20%. However, there are no comprehensive studies assessing the frequency of such variants across the age spectrum. We performed augmented whole-exome sequencing of peripheral blood samples from 404 patients with MDS and their related donors before allogeneic hematopoietic stem cell transplantation. Single-nucleotide and copy number variants in 233 genes were analyzed and interpreted. Germ line status was established by the presence of a variant in the patient and related donor or for those seen previously only as germ line alleles. We identified P/LP germ line variants in 28 of 404 patients with MDS (7%), present within all age deciles. Patients with P/LP variants were more likely to develop higher-grade MDS than those without (43% vs 25%; P = .04). There was no statistically significant difference in outcome parameters between patients with and without a germ line variant, but the analysis was underpowered. P/LP variants in bone marrow failure syndrome genes were found in 5 patients aged less than 40 years, whereas variants in DDX41 (n = 4), telomere biology disorder genes (n = 2), and general tumor predisposition genes (n = 17) were found in patients aged more than 40 years. If presumed germ line variants were included, the yield of P/LP variants would increase to 11%, and by adding suspicious variants of unknown significance, it would rise further to 12%. The high frequency of P/LP germ line variants in our study supports comprehensive germ line genetic testing for all patients with MDS regardless of their age at diagnosis.

摘要

在 40 岁或以下被诊断为骨髓增生异常综合征 (MDS) 的患者中,致病性/可能致病性 (P/LP) 种系变异的频率为 15%至 20%。然而,目前尚无全面研究评估这种变异在整个年龄谱中的频率。我们对 404 例 MDS 患者及其相关供者在异基因造血干细胞移植前的外周血样本进行了增强全外显子组测序。分析和解释了 233 个基因中的单核苷酸和拷贝数变异。通过在患者和相关供者中存在变异,或对于以前仅作为种系等位基因出现的变异,确定种系状态。我们在 404 例 MDS 患者中的 28 例(7%)中发现了 P/LP 种系变异,存在于所有年龄十分位数中。与无 P/LP 变异的患者相比,有 P/LP 变异的患者更有可能发展为高级别 MDS(43% vs 25%;P=0.04)。有和无种系变异的患者之间在预后参数方面没有统计学上的显著差异,但分析的效能不足。在 5 例年龄小于 40 岁的患者中发现了骨髓衰竭综合征基因中的 P/LP 变异,而在年龄大于 40 岁的患者中发现了 DDX41(n=4)、端粒生物学紊乱基因(n=2)和一般肿瘤易感性基因(n=17)中的变异。如果假定种系变异存在,则 P/LP 变异的检出率将增加到 11%,如果再加上可疑的意义不明的变异,则进一步增加到 12%。我们的研究中 P/LP 种系变异的高频率支持对所有 MDS 患者进行全面的种系基因检测,无论其诊断时的年龄如何。

相似文献

1
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.胚系倾向性变异在各年龄段骨髓增生异常综合征患者中均有发生。
Blood. 2022 Dec 15;140(24):2533-2548. doi: 10.1182/blood.2022015790.
2
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.胚系 DDX41 突变定义了一种独特的髓系肿瘤亚型。
Blood. 2023 Feb 2;141(5):534-549. doi: 10.1182/blood.2022018221.
3
The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.在诊断测序过程中发现的 DDX41 变异患者的临床和基因组特征。
Blood Adv. 2023 Dec 12;7(23):7346-7357. doi: 10.1182/bloodadvances.2023011389.
4
Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.临床实践中骨髓增生异常综合征的遗传易感性
Hematol Oncol Clin North Am. 2020 Apr;34(2):333-356. doi: 10.1016/j.hoc.2019.10.002. Epub 2020 Jan 6.
5
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.预后肿瘤测序panel 常能鉴定与遗传性血液恶性肿瘤相关的胚系变异。
Blood Adv. 2018 Jan 23;2(2):146-150. doi: 10.1182/bloodadvances.2017013037.
6
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.家族性骨髓增生异常综合征/急性髓系白血病中生殖系和体细胞变异的基因组分析。
Blood. 2015 Nov 26;126(22):2484-90. doi: 10.1182/blood-2015-04-641100. Epub 2015 Oct 22.
7
Aplastic anemia and clonal evolution: germ line and somatic genetics.再生障碍性贫血与克隆进化:种系与体细胞遗传学
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):74-82. doi: 10.1182/asheducation-2016.1.74.
8
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.胚系 DDX41 变异导致髓系肿瘤的遗传特征。
Blood. 2022 Aug 18;140(7):716-755. doi: 10.1182/blood.2021015135.
9
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?目前关于识别具有种系易感性的骨髓增生异常综合征的指南是否足够有力?
Br J Haematol. 2023 Apr;201(1):e5-e11. doi: 10.1111/bjh.18676. Epub 2023 Jan 30.
10
Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.有或无种系GATA2突变的骨髓衰竭、骨髓增生异常综合征和急性髓系白血病儿科患者清髓性异基因干细胞移植结局的比较
Biol Blood Marrow Transplant. 2020 Jun;26(6):1124-1130. doi: 10.1016/j.bbmt.2020.02.015. Epub 2020 Feb 20.

引用本文的文献

1
Germline Variant Burden Warrants Universal Genetic Testing in Pediatric Myeloid Leukemia.种系变异负荷表明小儿髓系白血病需进行普遍基因检测。
medRxiv. 2025 Jul 30:2025.07.29.25332166. doi: 10.1101/2025.07.29.25332166.
2
Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop.与种系基因变异相关的非典型淋巴增殖:2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Aug;487(2):275-286. doi: 10.1007/s00428-025-04189-0. Epub 2025 Aug 1.
3
Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective.

本文引用的文献

1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias.胚系变异解读实用指南:解析驱动血液系统恶性肿瘤、骨髓衰竭和慢性血细胞减少症的胚系变异。
Genet Med. 2022 Apr;24(4):931-954. doi: 10.1016/j.gim.2021.12.008. Epub 2022 Jan 19.
3
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
从拉丁美洲视角看骨髓增生异常综合征的遗传学进展
Genes (Basel). 2025 Jun 2;16(6):687. doi: 10.3390/genes16060687.
4
Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management.遗传性造血系统恶性肿瘤:优化诊断与管理的考量因素
Curr Oncol Rep. 2025 Jun 26. doi: 10.1007/s11912-025-01699-7.
5
Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study.具有种系易感性的髓系肿瘤基因检测指南的验证:一项前瞻性队列研究的结果
Clin Cancer Res. 2025 Jul 15;31(14):3062-3071. doi: 10.1158/1078-0432.CCR-24-4251.
6
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.有害的种系CHEK2变异导致造血系统恶性肿瘤的易感性。
Leukemia. 2025 May 7. doi: 10.1038/s41375-025-02635-1.
7
Overall cancer risk in people with deleterious germline variants.携带有害生殖系变异人群的总体癌症风险。
Haematologica. 2025 Sep 1;110(9):2076-2090. doi: 10.3324/haematol.2024.286887. Epub 2025 Feb 13.
8
Genetic Predisposition to Hematologic Malignancies.血液系统恶性肿瘤的遗传易感性
Cold Spring Harb Perspect Med. 2025 Feb 10. doi: 10.1101/cshperspect.a041585.
9
Myelodysplastic syndrome with dual germline RUNX1 and DDX41 variants: a rare genetic predisposition case.伴有双胚系RUNX1和DDX41变异的骨髓增生异常综合征:1例罕见的遗传易感性病例。
Fam Cancer. 2025 Jan 31;24(1):20. doi: 10.1007/s10689-025-00443-1.
10
Clonal hematopoiesis in cancer predisposition syndromes.癌症易感综合征中的克隆性造血
Int J Hematol. 2024 Dec 6. doi: 10.1007/s12185-024-03878-x.
供者克隆性造血与移植后受者结局
J Clin Oncol. 2022 Jan 10;40(2):189-201. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18.
4
Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.医生指导的基因筛查,以评估具有医学可操作性的疾病的个人风险:一项大型多中心队列研究。
BMC Med. 2021 Aug 18;19(1):199. doi: 10.1186/s12916-021-01999-2.
5
Germline predisposition to hematopoietic malignancies.胚系易感性致血液系统恶性肿瘤。
Hum Mol Genet. 2021 Oct 1;30(20):R225-R235. doi: 10.1093/hmg/ddab141.
6
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.靶向基因panel 检测到患有血液系统恶性肿瘤和至少一种其他独立癌症的患者中存在高频的致病性种系变异。
Leukemia. 2021 Nov;35(11):3245-3256. doi: 10.1038/s41375-021-01246-w. Epub 2021 Apr 13.
7
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities.遗传性造血系统恶性肿瘤易感性:克服障碍,探索机遇。
Br J Haematol. 2021 Aug;194(4):663-676. doi: 10.1111/bjh.17247. Epub 2020 Dec 5.
8
Next-Generation Sequencing of in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.髓系肿瘤的二代测序可提高种系变异的检测率。
Front Oncol. 2021 Jan 28;10:582213. doi: 10.3389/fonc.2020.582213. eCollection 2020.
9
Germline variants drive myelodysplastic syndrome in young adults.生殖系变异导致年轻成年人患骨髓增生异常综合征。
Leukemia. 2021 Aug;35(8):2439-2444. doi: 10.1038/s41375-021-01137-0. Epub 2021 Jan 28.
10
Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.ITGA2B/ITGB3变异评估指南规范:临床基因组资源血小板疾病变异评估小组
Blood Adv. 2021 Jan 26;5(2):414-431. doi: 10.1182/bloodadvances.2020003712.